ONC: BeOne Medicines Ltd.
Performance
ONC +30.43%
Watchlist
Select an item
Summary
ONC at a glance
ONC returned +30.43% over the past year and +2.71% a year over five years. Its worst drop in that year was -31.05%, smaller than 55% of stocks on Redstone, and its Sharpe ratio of 0.82 beats 67% of stocks on Redstone. It pays no dividends.
Current Drawdown
0.00%
Rolling Volatility
42.03%
Actions
Metrics
Risk Indicators
Alpha22.16%
Beta0.73x
Sharpe0.82
Sortino1.28
Omega1.15
Calmar0.98
Martin1.87
Profile
About ONC
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $47.2B
- Listed
- Feb 2016
- Employees
- 12,000
- Headquarters
- Basel
- Website
- beonemedicines.com
Comparisons